Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort

Anti-CD20 antibodies and cladribine are established therapies for active relapsing multiple sclerosis (RMS). Increasing evidence suggests that switching between these therapies may be beneficial in patients with ongoing disease activity under current treatment. In this multicenter retrospective stud...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Franz Felix Konen, Steffen Pfeuffer, Konstantin Fritz Jendretzky, Klaus Gehring, Birte Elias-Hamp, Kurt-Wolfram Sühs, Stephan Halle, Korbinian Brand, Ralf Lichtinghagen, Eline Willemse, Marc Pawlitzki, Jens Kuhle, Sven G. Meuth, Christoph Kleinschnitz, Refik Pul, Thomas Skripuletz
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-01-01
Serija:	Neurotherapeutics
Teme:	Active multiple sclerosis Anti-CD20-Therapy Cladribine Switch
Online dostop:	http://www.sciencedirect.com/science/article/pii/S1878747925002909
Oznake:	Označite Brez oznak, prvi označite!